MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...

The following is a summary of “Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review ...

The company needs to win over haematologists to its new treatment, as biosimilar versions of rituximab are expected to hit the European market in 2017, and could be close behind in the US.

The FDA has approved Genentech’s subcutaneous version of the cancer drug rituximab, allowing for a more convenient injection lasting minutes, rather than several hours. Branded as Rituxan Hycela ...

One of these therapies, rituximab, a chimeric monoclonal antibody against human CD20 (hCD20; a B-cell-specific surface marker), depletes B cells and has been effective in several autoimmune ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the ...

To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

People with multiple sclerosis (MS) may receive less frequent infusions of rituximab without increasing their chances of relapse or disease progression, according to a real-world study from Norway.

Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...